secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001739104-23-000021
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco reports Q3 2023 net loss of $1,096M on $1,042M goodwill impairment; raises adjusted EPS guidance
--------------------------------------------------------------------------------

- Revenue $1,068M (+4% reported, +5% CC); Pet Health +6% CC, Farm Animal +4% CC.
- Reported net loss $1,096M includes $1,042M goodwill impairment; adjusted EPS $0.18 (up 6% YoY).
- Full-year 2023 guidance tightened: revenue $4,360-4,400M, adj. EPS $0.88-0.94 (prior $0.80-0.89).
- Net leverage ratio 5.7x; Q4 guidance: revenue $978-1,018M, adj. EPS $0.07-0.13.
- CEO: innovation pipeline Credelio Quattro, Bovaer, Zenrelia on track for H1 2024 US approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000173910423000021/0001739104-23-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000173910423000021/elan-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001739104-23-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer